LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Statins May Help Block Transmission of Lyme Disease

By LabMedica International staff writers
Posted on 31 May 2016
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).
A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease.

Lyme disease is a systemic disorder caused by the spirochete bacterium Borrelia burgdorferi. This bacterium is transmitted to mammalian hosts from arthropod vectors, specifically Ixodes spp. ticks. Lyme disease is the most prevalent arthropod borne disease in the USA with over 25,000 cases confirmed by the Centers for Disease Control and Prevention in 2014.

Investigators at the University of Texas at San Antonio (USA) decided to attack B. burgdorferi through its 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which serves as a rate limiting enzyme of the mevalonate pathway that contributes to the synthesis of components critical for building the bacterium's cell wall.

In this study C3H/HeN mice, with or without statin treatment, were infected with 1000 spirochetes per mouse. The spirochetes were found to spread to all tissues with a few exceptions. Though there was no significant difference in bacterial dissemination to distal tissues between statin-treated and untreated mice, the investigators wanted to determine whether there were differences in the numbers of bacteria migrating to specific tissues. To that end, total genomic DNA was extracted from a portion of skin, spleen, right inguinal lymph node, and right tibiotarsal joint and subjected to quantitative real-time PCR analysis using primers specific for B. burgdorferi genes.

Results published in the March 16, 2016, online edition of the journal Microbes and Infection revealed that there was a significant decrease in the numbers of bacteria in each of the tissues tested with the exception of the joints. There were higher levels of reduction seen in the lymph nodes and spleens of mice treated with simvastatin when compared to the same tissues from mice treated with lovastatin, while there was a higher level of reduction in the skin of lovastatin-treated mice.

"We have figured out that there is one enzyme in the Lyme disease bacteria that is essential for creating its cell wall, which would allow the Lyme disease bacteria to live and cause infection," said senior author Dr. Janakiram Seshu, associate professor of biology at the University of Texas at San Antonio. "We discovered that this enzyme can be inhibited by statins, which means that one class of drugs could reduce the number of infectious bacteria in the reservoir hosts. First we want to determine how statins can be used to stop the growth of the pathogen and how we can exploit these findings to our benefit. Our hope is that if we reduce the number of viable organisms in infected reservoir hosts then we can block the transmission to a point that the disease does not affect humans significantly in many areas of the USA."

Related Links:
University of Texas at San Antonio

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more